We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Macrophage Role in Infection Determined by PI-3 Kinase-Gamma Signaling

By LabMedica International staff writers
Posted on 29 Sep 2016
Cancer researchers have identified a molecule responsible for the signal that converts macrophages from an inflammatory, immunostimulatory mode in acute infections to an anti-inflammatory, immunosuppressive mode that supports tumor development and growth.

Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer. More...
In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T-cells, while highly abundant macrophages in cancer and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote tumor growth.

Investigators at the University of California, San Diego (USA) reported in the September 19, 2016, online issue of the journal Nature that results of experiments carried out with mouse models had allowed them to identify the macrophage enzyme PI-3 kinase-gamma (PI3K-gamma) as the controller of a critical switch between immune stimulation and suppression during inflammation and cancer.

PI3K-gamma signaling induced a transcriptional program that promoted immune suppression during inflammation and tumor growth. In contrast, selective inactivation of macrophage PI3K-gamma promoted an immunostimulatory transcriptional program that restored CD8+ T-cell activation and cytotoxicity and synergized with checkpoint inhibitor therapy to promote tumor regression and extend survival in mouse models of cancer.

“Immunotherapies, such as T-cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said senior author Dr. Judith A. Varner, professor of pathology and medicine at the University of California, San Diego. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”

Related Links:
University of California, San Diego


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.